Stereotaxis (NYSEAMERICAN:STXS) Announces Earnings Results, Misses Estimates By $0.02 EPS

Stereotaxis (NYSEAMERICAN:STXS) issued its earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Zacks reports. The firm had revenue of $8.93 million during the quarter, compared to analyst estimates of $9.60 million. Stereotaxis had a negative return on equity of 130.84% and a negative net margin of 74.24%.

Here are the key takeaways from Stereotaxis’ conference call:

• GenesisX and Synchrony are beginning to contribute to capital sales. Stereotaxis reported a pipeline of a couple dozen GenesisX opportunities and about 50 Synchrony systems; the company expects upcoming GenesisX installations and new X-ray compatibility, including a collaboration with Canon, to support broader adoption.
• MAGiC catheter supply remains a major constraint. Osypka’s production did not increase in the third quarter, leaving about $1.9 million of disposable orders unfilled entering Q4. Stereotaxis expects supply relief in early 2027, pending regulatory milestones for an alternative supply source, and said the shortage continues to limit procedures and recurring revenue.
• Third-quarter revenue rose 20% year over year to $8.9 million, while recurring revenue increased 6% to $5.9 million but fell 4% sequentially. Gross margin was 45%; operating and net losses were both $6.5 million, and adjusted operating expenses increased from a year earlier, partly due to Robocath-related costs.
• Stereotaxis received $12 million upfront through a convertible-note financing and has the option to draw another $12 million after a regulatory milestone. The company said pro forma cash is $16 million, with up to $28 million available, and management sees a path to profitability next year as recurring revenue grows and capital sales become more consistent.

Stereotaxis Stock Down 9.6%

Shares of STXS stock opened at $1.03 on Wednesday. The company has a market cap of $103.21 million, a P/E ratio of -4.29 and a beta of 1.40. The business has a 50 day moving average of $1.16 and a two-hundred day moving average of $1.66. Stereotaxis has a 52 week low of $0.80 and a 52 week high of $2.89.

Analyst Ratings Changes

A number of equities analysts have commented on STXS shares. Citizens Jmp decreased their price objective on shares of Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 27th. TD Cowen lowered their target price on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Finally, Citigroup reissued an “outperform” rating on shares of Stereotaxis in a report on Thursday, August 27th. Five investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $3.38.

About Stereotaxis

Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias. The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.